Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action (Q34544845)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action |
scientific article |
Statements
1 reference
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action (English)
1 reference
Mario A Eisenberger
1 reference
Menachem Laufer
1 reference
Nicholas J Vogelzang
1 reference
Oliver Sartor
1 reference
Donald Thornton
1 reference
Blake Lee Neubauer
1 reference
Victoria Sinibaldi
1 reference
Gary Lieskovsky
1 reference
Michael A Carducci
1 reference
Mariana Zahurak
1 reference
Derek Raghavan
1 reference
1 January 2004
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference